Surgical treatment of nontuberculous mycobacterial lung disease

被引：14

作者：

Shiraishi Y. ^{[1
]}

机构：

[1] Section of Chest Surgery, Fukujuji Hospital, Kiyose-shi, Tokyo 204-8522

来源：

General Thoracic and Cardiovascular Surgery | 2014年 / 62卷 / 8期

关键词：

Adjunctive resectional surgery; Chemotherapy; Multidisciplinary approach; Nontuberculous mycobacterial lung disease;

D O I：

10.1007/s11748-014-0402-1

中图分类号：

学科分类号：

摘要：

While the prevalence of pulmonary tuberculosis has been decreasing, the prevalence of nontuberculous mycobacterial lung disease has been increasing. Unlike tuberculosis, nontuberculous mycobacterial disease is not communicable. However, their indolent nature may result in extensive parenchymal destruction, causing respiratory failure and vulnerability to airway infection. Nontuberculous mycobacterial lung disease, therefore, has been becoming a significant health problem. According to the 2007 American Thoracic Society/Infectious Diseases Society of America statement on nontuberculous mycobacterial diseases, the primary treatment is a multidrug treatment regimen. However, its efficacy is less than satisfactory for Mycobacterium avium complex lung disease, which is the most common type of nontuberculous mycobacterial lung diseases, and for Mycobacterium abscessus lung disease, which is notoriously resistant to chemotherapeutic drugs. The statement, therefore, has proposed a multidisciplinary treatment approach for these types of nontuberculous mycobacterial lung diseases: a combination of multidrug treatment regimen and adjuvant resectional surgery. This review covers the rationale, indication, procedure, and outcome of surgical treatment of nontuberculous mycobacterial lung disease. The rationale of surgery is to prevent disease progressing by removing the areas of lung most affected, harboring the largest amounts of mycobacteria. The indications for surgery include a poor response to drug therapy, the development of macrolide-resistant disease, or the presence of a significant disease-related complication such as hemoptysis. The surgical procedures of choice are various types of pulmonary resections, including wedge resection, segmentectomy, lobectomy, or pneumonectomy. The reported series have achieved favorable treatment outcomes in surgically treated patients with acceptable morbidity and mortality rates. © 2014 The Japanese Association for Thoracic Surgery.

引用

页码：475 / 480

页数：5

共 32 条

[1]

Adjemian J., Olivier K.N., Seitz A.E., Holland S.M., Prevots D.R., Prevalence of nontuberculous mycobacterial lung disease in US Medicare beneficiaries, Am J Respir Crit Care Med, 185, pp. 881-886, (2012)

[2]

Prevots D.R., Shaw P.A., Strickland D., Jackson L.A., Raebel M.A., Blosky M.A., Et al., Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems, Am J Respir Crit Care Med, 182, pp. 970-976, (2010)

[3]

Morimoto K., Iwai K., Uchimura K., Okumura M., Yoshiyama T., Yoshimori K., Et al., A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan, Ann Am Thorac Soc, 11, pp. 1-8, (2014)

[4]

Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F., Et al., An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases, Am J Respir Crit Care Med, 175, pp. 367-416, (2007)

[5]

Guidelines for surgical therapy for pulmonary nontuberculous mycobacterial diseases, Kekkaku, 86, pp. 41-42, (2011)

[6]

Sakatani M., The non-tuberculous mycobacteriosis, Kekkaku, 80, 1, pp. 25-30, (2005)

[7]

Diagnosis and treatment of disease caused by non-tuberculous mycobacteria, Am J Respir Crit Care Med, 156, (1997)

[8]

Opinions of Japanese Society for Tuberculosis committee on therapy of atypical mycobacterium infections, Kekkaku, 73, pp. 599-605, (1998)

[9]

Guidelines for chemotherapy of pulmonary nontuberculous mycobacterial disease - 2012 revised version, Kekkaku, 88, pp. 29-32, (2013)

[10]

Wallace Jr. R.J., Brown B.A., Griffith D.E., Girard W.M., Murphy D.T., Clarithromycin regimens for pulmonary Mycobacterium avium complex: The first 50 patients, American Journal of Respiratory and Critical Care Medicine, 153, 6 I, pp. 1766-1772, (1996)

← 1 2 3 4 →